January 16, 2018 / 12:00 PM / in a year

Merck's Keytruda succeeds in key lung cancer trial

Jan 16 (Reuters) - Merck & Co Inc said on Tuesday that a key late-stage study testing its blockbuster drug Keytruda as a treatment for a type of lung cancer was successful.

The trial, which tested Keytruda as a first line treatment, met its main goals of preventing cancer from worsening and extending the overall survival of patients with metastatic non-squamous non-small-cell lung cancer.

Keytruda has previously been approved to treat several forms of cancer including stomach cancer and skin cancer. (Reporting by Tamara Mathias in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below